» Articles » PMID: 28595241

Stratifying Patients with Peripheral Neuropathic Pain Based on Sensory Profiles: Algorithm and Sample Size Recommendations

Abstract

In a recent cluster analysis, it has been shown that patients with peripheral neuropathic pain can be grouped into 3 sensory phenotypes based on quantitative sensory testing profiles, which are mainly characterized by either sensory loss, intact sensory function and mild thermal hyperalgesia and/or allodynia, or loss of thermal detection and mild mechanical hyperalgesia and/or allodynia. Here, we present an algorithm for allocation of individual patients to these subgroups. The algorithm is nondeterministic-ie, a patient can be sorted to more than one phenotype-and can separate patients with neuropathic pain from healthy subjects (sensitivity: 78%, specificity: 94%). We evaluated the frequency of each phenotype in a population of patients with painful diabetic polyneuropathy (n = 151), painful peripheral nerve injury (n = 335), and postherpetic neuralgia (n = 97) and propose sample sizes of study populations that need to be screened to reach a subpopulation large enough to conduct a phenotype-stratified study. The most common phenotype in diabetic polyneuropathy was sensory loss (83%), followed by mechanical hyperalgesia (75%) and thermal hyperalgesia (34%, note that percentages are overlapping and not additive). In peripheral nerve injury, frequencies were 37%, 59%, and 50%, and in postherpetic neuralgia, frequencies were 31%, 63%, and 46%. For parallel study design, either the estimated effect size of the treatment needs to be high (>0.7) or only phenotypes that are frequent in the clinical entity under study can realistically be performed. For crossover design, populations under 200 patients screened are sufficient for all phenotypes and clinical entities with a minimum estimated treatment effect size of 0.5.

Citing Articles

Innovations in acute and chronic pain biomarkers: enhancing diagnosis and personalized therapy.

Mackey S, Aghaeepour N, Gaudilliere B, Kao M, Kaptan M, Lannon E Reg Anesth Pain Med. 2025; 50(2):110-120.

PMID: 39909549 PMC: 11877092. DOI: 10.1136/rapm-2024-106030.


Nociplastic Pain in Endometriosis: A Scoping Review.

Gentles A, Goodwin E, Bedaiwy Y, Marshall N, Yong P J Clin Med. 2025; 13(24).

PMID: 39768444 PMC: 11727753. DOI: 10.3390/jcm13247521.


Pain profiles and variability in temporal summation of pain and conditioned pain modulation in pain-free individuals and patients with low back pain, osteoarthritis, and fibromyalgia.

Petersen K, ONeill S, Blichfeldt-Eckhardt M, Nim C, Arendt-Nielsen L, Vaegter H Eur J Pain. 2024; 29(3):e4741.

PMID: 39387150 PMC: 11755398. DOI: 10.1002/ejp.4741.


8. Herpes zoster and post herpetic neuralgia.

Adriaansen E, Jacobs J, Vernooij L, van Wijck A, Cohen S, Huygen F Pain Pract. 2024; .

PMID: 39364882 PMC: 11683194. DOI: 10.1111/papr.13423.


Could biomarkers mean better pain treatment?.

Mitchell Crow J Nature. 2024; 633(8031):S28-S30.

PMID: 39322724 DOI: 10.1038/d41586-024-03004-1.


References
1.
Demant D, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup N . The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014; 155(11):2263-73. DOI: 10.1016/j.pain.2014.08.014. View

2.
Attal N, de Andrade D, Adam F, Ranoux D, Teixeira M, Galhardoni R . Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016; 15(6):555-65. DOI: 10.1016/S1474-4422(16)00017-X. View

3.
Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

4.
Truini A, Padua L, Biasiotta A, Caliandro P, Pazzaglia C, Galeotti F . Differential involvement of A-delta and A-beta fibres in neuropathic pain related to carpal tunnel syndrome. Pain. 2009; 145(1-2):105-9. DOI: 10.1016/j.pain.2009.05.023. View

5.
Simpson D, Schifitto G, Clifford D, Murphy T, Durso-De Cruz E, Glue P . Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010; 74(5):413-20. PMC: 2816006. DOI: 10.1212/WNL.0b013e3181ccc6ef. View